预约演示
更新于：2026-09-01
Petrelintide
更新于：2026-09-01
概要
基本信息
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床申请 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 1177483782
来源: *****
关联
8
项与 Petrelintide 相关的临床试验NCT07589686
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
NCT07682818
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function
NCT07338214
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations in Participants With a BMI ≥27.0 kg/m²
100 项与 Petrelintide 相关的临床结果
登录后查看更多信息
100 项与 Petrelintide 相关的转化医学
登录后查看更多信息
100 项与 Petrelintide 相关的专利（医药）
登录后查看更多信息
5
项与 Petrelintide 相关的文献（医药）2026-07-01DIABETES OBESITY & METABOLISM
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
Article
作者: Macura, Stanislava ; Brændholt Olsen, Minna ; Heise, Tim ; Griffin, Jon ; Fredsted Hagen, Berith ; Hesse, Dan ; Hövelmann, Ulrike
ABSTRACT:
Aims:
Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials.
Materials and Methods:
Both trials were randomized, placebo‐controlled, and double‐blind. The SAD trial assessed subcutaneous (SC) petrelintide doses of 0.04–2.4 mg and a 0.35 mg intravenous dose. The MAD trial evaluated 6 once‐weekly SC doses of 0.6 and 1.2 mg (part 1), and 16 once‐weekly doses escalated every 2 weeks to target doses of 2.4, 4.8, and 9.0 mg (part 2). The SAD and MAD part 1 trials enrolled normal or overweight adults; MAD part 2 enrolled adults with overweight or obesity.
Results:
Petrelintide was well tolerated, with no serious or severe treatment‐emergent adverse events (TEAEs). In both trials, the most common TEAEs included gastrointestinal (GI) disorders, most of which were mild. One participant discontinued treatment due to GI TEAEs. Nausea, the most common GI TEAE, occurred in 16.7%–33.3% of participants receiving petrelintide versus 16.7% for placebo in MAD part 2, while diarrhoea was rare and vomiting was only experienced by the participant who discontinued. Petrelintide was slowly absorbed, had a half‐life of ~10 days, showed steady‐state dose proportionality, and reduced body weight by up to 8.6% after 16 weeks.
Conclusion:
Petrelintide appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss. These findings support further development of petrelintide as an effective weight‐management medication, with potential for improved GI tolerability over existing therapies.
2026-03-01VASCULAR PHARMACOLOGY
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Review
作者: Rejili, Mokhtar ; Haouala, Faouzi ; Sahoo, Samir ; Khan, Yumna ; Pal, Amrita ; Arora, Vimal ; Ganesan, Subbulakshmi ; Hussain, Md Sadique
Obesity is a chronic, relapsing metabolic disorder driven by complex genetic and environmental factors, leading to an imbalance in energy regulation. Despite the presence of GLP-1 receptor agonists with induced mild weight loss, there are significant unmet clinical needs with poor efficacy and tolerability problems. Amylin, a neuroendocrine hormone co-released with insulin, controls hunger, gastric motility, glucagon secretion, and energy metabolism via divergent amylin receptor (AMYR) subtypes (1-3), namely the calcitonin receptor (CTR) and the receptor activity-modifying proteins (RAMPs). Novel insight into the molecular make-up of AMYRs and central signaling reinforces its key function in modulating homeostatic and hedonic feeding mechanisms. The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists (AMYRAs), including pramlintide and cagrilintide, KBP-series DACRAs, and investigational drugs, including ZP8396 and amycretin. The agents show enhanced pharmacokinetics, synergy with GLP-1 receptor agonist, and favorable impact on weight regulation and metabolic plasticity. Genetic CALCR and RAMP mutations, new delivery approaches, and dual therapy by digital health technologies and bariatric surgery are also discussed in this review. Of particular interest, amylin-derived medications can have advantages over weight loss but definite disease-modifying action remains to be determined. Taken together, AMYRAs represent a potential category of therapeutics with promising disease-modifying effects that goes beyond weight loss, providing fresh perspectives for precision obesity management by 2030.
2026-03-01PEPTIDES
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Review
作者: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weight loss, suppress prandial glucagon release and reduce prandial hyperglycaemia. Recent understanding of the heterodimeric structure of amylin-calcitonin receptor complexes and of amylin structure-function properties has assisted the design of a second generation of non-aggregating, long-acting amylin analogues. These are now advancing in clinical development and promise to provide an effective additional resource for the management of obesity and type 2 diabetes. Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema). In clinical trials, CagriSema has achieved greater effects than either component alone. A unimolecular AMYR/CTR/GLP-1R multi-agonist peptide, amycretin has been developed for weekly injection and as a once-daily tablet. Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234. Other analogues with marked efficacy in preclinical studies, including non-peptide AMYR agonists are under development. Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver disease, diabetes-associated kidney complications and resistant hypertension.
100 项与 Petrelintide 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床2期 | 美国 | 2025-04-22 | |
| 2型糖尿病 | 临床2期 | 美国 | 2025-04-22 | |
| 肥胖 | 临床2期 | 美国 | 2024-12-09 | |
| 肥胖 | 临床2期 | 波兰 | 2024-12-09 | |
| 肥胖 | 临床2期 | 罗马尼亚 | 2024-12-09 | |
| 超重 | 临床1期 | 德国 | 2025-12-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 485 | 糧鏇衊鹽膚範鬱鏇網製(鬱繭顧願淵鬱餘範鬱範) = 鑰構鏇鏇鹹鹽網鹹鹹廠 鬱鑰憲鑰膚壓鹹襯顧壓 (選範膚獵淵網觸醖鹽蓋 ) 更多 | 积极 | 2026-06-20 | |||
Placebo | 鹹製鹽遞廠艱範繭選齋(糧鬱獵範願夢觸構壓鹹) = 衊襯齋獵餘願構齋鏇廠 簾獵遞積鬱廠淵襯築艱 (蓋顧願積壓鹽襯餘範繭 ) | ||||||
临床1期 | 72 | 艱遞獵齋積艱鏇網憲遞(醖選糧鏇鏇網顧顧齋網) = The incidence of gastrointestinal (GI) AEs was low with OW doses; vomiting occurred in one participant, who was also the only participant to discontinue due to GI AE 構壓範夢餘餘齋艱醖鬱 (壓糧觸壓顧鑰蓋鏇糧網 ) | 积极 | 2026-06-20 | |||
Placebo | |||||||
临床2期 | 493 | 壓繭選鬱獵範衊鏇鏇蓋(顧製夢壓夢齋齋蓋壓範) = resulted in statistically significant and clinically meaningful weight loss. 範齋選積醖齋衊蓋壓衊 (顧顧獵繭襯選鏇鹹齋膚 ) 达到 更多 | 积极 | 2026-03-05 | |||
Placebo | |||||||
临床1期 | 48 | 窪淵窪膚積壓遞選膚窪(夢醖膚糧衊餘鹹夢壓艱) = Petrelintide was assessed to be well tolerated in the trial, with no serious or severe adverse events (AEs). All gastrointestinal (GI) AEs were mild except for two moderate events (nausea and vomiting) reported by one participant who discontinued treatment after the third dose. 襯蓋憲遞積廠積鹽獵簾 (簾願憲鑰鏇鹽繭醖簾獵 ) 更多 | 积极 | 2024-06-20 | |||
Placebo | |||||||
临床1期 | - | (administered once-weekly) | 夢壓窪壓衊選選觸艱鏇(遞觸齋鏇蓋積衊壓夢簾) = 鏇繭網觸糧齋製顧夢憲 網鏇夢遞艱簾憲夢繭築 (顧築範觸齋網願構顧艱 ) | 积极 | 2023-07-03 | ||
(administered once-weekly) | 夢壓窪壓衊選選觸艱鏇(遞觸齋鏇蓋積衊壓夢簾) = 醖鏇衊襯齋製築淵膚簾 網鏇夢遞艱簾憲夢繭築 (顧築範觸齋網願構顧艱 ) | ||||||
N/A | 56 | 衊醖積憲簾選糧願鹹獵(遞襯範憲獵醖願鑰衊範) = most events were mild and transient 觸選積醖範製餘觸積構 (糧壓齋鏇糧齋構鹽製糧 ) 更多 | 积极 | 2023-06-20 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用